Table 3: Response to tyrisine kinase (i.e. imatinib mesylate) in patients with myeloid neoplasms associated with ETV6-PDGFRB rearrangement.

Study Male/Female ETV6-PDGFRB patients/Other PDGFR rearrangements Tyrosine kinase (i.e. imatinib mesylate) Dosage regimen Response to treatment
Apperley, et al. [17] 4/0 4/0 From 400 to 800 mg/daily No residual disease at 9 to 12 months after the initiation of the treatment
David, et al. [36] 10/2 8/4 From 200 to 800 mg/daily Hematological response: 49 months (19-60 months)

Cytogenetic response: 47 months (16-59 months)

10 patients were still alive at the time of publication (including all ETV6-PDGFRB patients)

Arefi, et al. [8] 8/2 2/8 400 mg/daily 7 patients achived complete cytologic and hematological reponse including both ETV6-PDGFRB patients - median follow-up = 19 months